Clinical trial · no report yet · Early phase 1
CLONEVO
(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
- NCT03837821 ↗
- Active not recruiting
- Weill Medical College of Cornell University
- 22 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
- Phase
- Early phase 1
- Status
- Active not recruiting
- Conditions
- Bladder Cancer
- Interventions
- Abemaciclib
- Arms
- All Subjects · Experimental
- Enrollment
- 20
- Primary outcomes
- Change in cell-cycle dynamics between pre- and post-Abemaciclib tumor samples
- Sponsor
- Weill Medical College of Cornell University with Eli Lilly and Company
- Start
- Feb 5, 2019
- Primary completion
- Jul 2, 2024
- Results posted
- No
- Registry record
- NCT03837821 · updated Nov 18, 2025